253 related articles for article (PubMed ID: 24727881)
1. [Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type)].
Servello A; Andreozzi P; Bechini F; De Angelis R; Pontecorvo ML; Vulcano A; Cerra E; Vigliotta MT; Artini M; Selan L; Ettorre E
Minerva Med; 2014 Apr; 105(2):167-74. PubMed ID: 24727881
[TBL] [Abstract][Full Text] [Related]
2. Rivastigmine in vascular dementia.
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
Expert Opin Pharmacother; 2004 Jun; 5(6):1399-410. PubMed ID: 15163283
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
[TBL] [Abstract][Full Text] [Related]
4. Rivastigmine for vascular cognitive impairment.
Birks J; McGuinness B; Craig D
Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
[TBL] [Abstract][Full Text] [Related]
5. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
6. Rivastigmine in subcortical vascular dementia: an open 22-month study.
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
J Neurol Sci; 2002 Nov; 203-204():141-6. PubMed ID: 12417373
[TBL] [Abstract][Full Text] [Related]
7. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
9. Rivastigmine in vascular dementia.
Vincent S; Lane R
Int Psychogeriatr; 2003; 15 Suppl 1():201-5. PubMed ID: 16191241
[TBL] [Abstract][Full Text] [Related]
10. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
11. Rivastigmine for subcortical vascular dementia.
Román GC
Expert Rev Neurother; 2005 May; 5(3):309-13. PubMed ID: 15938663
[TBL] [Abstract][Full Text] [Related]
12. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients.
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
Am J Alzheimers Dis Other Demen; 2003; 18(5):265-72. PubMed ID: 14569643
[TBL] [Abstract][Full Text] [Related]
13. Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study.
Moretti R; Torre P; Antonello RM; Cazzato G; Griggio S; Ukmar M; Bava A
Int J Clin Pract; 2004 Apr; 58(4):346-53. PubMed ID: 15161118
[TBL] [Abstract][Full Text] [Related]
14. aChE and BuChE inhibition by rivastigmin have no effect on peripheral insulin resistance in elderly patients with Alzheimer disease.
Isik AT; Bozoglu E; Eker D
J Nutr Health Aging; 2012 Feb; 16(2):139-41. PubMed ID: 22323348
[TBL] [Abstract][Full Text] [Related]
15. Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: a controlled, open 24-month study of 246 patients.
Moretti R; Torre P; Antonello RM; Cattaruzza T; Cazzato G
Am J Alzheimers Dis Other Demen; 2004; 19(6):333-9. PubMed ID: 15633941
[TBL] [Abstract][Full Text] [Related]
16. Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia.
Moretti R; Torre P; Antonello RM; Cazzato G; Pizzolato G
Am J Alzheimers Dis Other Demen; 2008; 23(2):167-76. PubMed ID: 18184948
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study.
Ballard C; Sauter M; Scheltens P; He Y; Barkhof F; van Straaten EC; van der Flier WM; Hsu C; Wu S; Lane R
Curr Med Res Opin; 2008 Sep; 24(9):2561-74. PubMed ID: 18674411
[TBL] [Abstract][Full Text] [Related]
18. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
19. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Bullock R
Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
[TBL] [Abstract][Full Text] [Related]
20. [The effect of rivastigmine on cognitive functions and regional cerebral blood flow in Alzheimer's disease and vascular dementia: follow-up for 2 years].
Lipczyńska-Łojkowska W; Ryglewicz D; Jedrzejczak T; Jakubowska T; Kotapka-Minc S; Sienkiewicz-Jarosz H; Bochyńska A
Neurol Neurochir Pol; 2004; 38(6):471-81. PubMed ID: 15654671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
